Last A$2.01 AUD
Change Today +0.045 / 2.29%
Volume 2.8M
As of 2:10 AM 08/21/14 All times are local (Market data is delayed by at least 15 minutes).

acrux ltd (ACR) Snapshot

Open
A$2.00
Previous Close
A$1.97
Day High
A$2.06
Day Low
A$1.95
52 Week High
09/2/13 - A$3.22
52 Week Low
06/6/14 - A$0.75
Market Cap
334.7M
Average Volume 10 Days
1.8M
EPS TTM
A$0.17
Shares Outstanding
166.5M
EX-Date
09/4/14
P/E TM
11.8x
Dividend
A$0.09
Dividend Yield
9.95%
Current Stock Chart for ACRUX LTD (ACR)

Related News

No related news articles were found.

acrux ltd (ACR) Related Businessweek News

No Related Businessweek News Found

acrux ltd (ACR) Details

Acrux Limited is engaged in the development and commercialization of healthcare products in Australia, Switzerland, the United States, and internationally. Its marketed products comprise Axiron for the treatment of testosterone deficiency in men; Recuvyra for pain relief of dogs; and Evamist for menopausal symptoms. The company’s product under registration study includes Estradiol MDTS for menopausal symptoms. It is also developing products, which are in formulation stage for the treatment of non-melanoma skin cancer, anti-fungal, pain and inflammation, and other diseases, as well as developing product for the treatment of animal health. The company was founded in 1998 and is headquartered in West Melbourne, Australia.

Founded in 1998

acrux ltd (ACR) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

acrux ltd (ACR) Key Developments

Acrux Limited Declares Fully Franked Final Dividend Payable on September 22, 2014

Acrux declared a final dividend for 2013/14 financial year of 8 cents per share, fully franked. The record date for entitlement to the dividend is 8 September 2014 and the estimated date for dispatch of payment is 22 September 2014.

Acrux Limited Announces Audited Consolidated Earnings Results for the Year Ended June 30, 2014

Acrux Limited announced audited consolidated earnings results for the year ended June 30, 2014. For the year, the company reported revenue of AUD 53,859,000 against AUD 16,528,000 a year ago. Profit before income tax was AUD 43,857,000 against AUD 10,041,000 a year ago. Net profit attributable to members of the parent entity was AUD 27,970,000 or 16.80 cents basic and diluted per share against AUD 6,926,000 or 4.16 cents basic and diluted per share a year ago. Cash flows from operating activities were AUD 36,371,000 against AUD 6,335,000 a year ago. Purchase of plant and equipment was AUD 39,000 against AUD 30,000 a year ago.

Acrux Limited Announces Sales Results for the Fourth Quarter and Year Ended June 30, 2014

Acrux Limited announced sales results for the fourth quarter and year ended June 30, 2014. For the quarter, the company announced net sales of $47.1 million up from $39.5 million for the previous quarter to March 31, 2014. For the year, the company announced net sales of $1,811 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACR:AU A$2.01 AUD +0.045

ACR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $42.32 USD +0.18
AbbVie Inc $54.96 USD -0.10
Auxilium Pharmaceuticals Inc $18.55 USD +0.78
Endo International PLC $63.28 USD -0.53
View Industry Companies
 

Industry Analysis

ACR

Industry Average

Valuation ACR Industry Range
Price/Earnings 11.1x
Price/Sales 6.2x
Price/Book 5.9x
Price/Cash Flow 11.2x
TEV/Sales 6.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACRUX LTD, please visit www.acrux.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.